n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, October 31st, 2017

The QualityStocks
Daily Stock List

graphic
graphic

DOCASA, Inc. (DCSA)

MarketWatch, Barchart, and Iconstockalerts reported on DOCASA, Inc. (DCSA), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, DOCASA, Inc. centers on investing in the fast-growing specialty coffee market, primarily in the United Kingdom (UK). The Company, by way of its subsidiary, Department of Coffee and Social Affairs Ltd. (London, England) has established and is growing an award-winning, market leading UK specialty coffee shop and online retail business. Department of Coffee and Social Affairs served its first coffee in December 2010 at Leather Lane, London. DOCASA is headquartered in Schaumburg, Illinois.

During the period December 2016 through February 2017, DOCASA opened four new shops in Kingston, Whitechapel, and Bank Street in London, and also one shop in Bristol. DOCASA’s stores sell proprietary coffee and related products, as well as complementary food and snacks.

Furthermore, DOCASA is pursuing franchising and/or licensing of its branded shops and premium product offerings outside of the UK. This is in nations where the premium coffee market is quickly expanding.

DOCASA, via its award-winning subsidiary, Department of Coffee and Social Affairs Limited, earlier announced the securing of its first coffee shop site in Manchester, UK. The new site is on the ground floor of Faulkner House, a 25,000-sq. ft. building of serviced offices, in Manchester's Piccadilly Gardens area.

The new site will be the Department of Coffee and Social Affairs' flagship store and barista training hub in the northern part of England. Additionally, the site will act as a co-work space for professionals, with hot desks, breakout spaces, and meeting rooms available to rent by the hour.

DOCASA, through Department of Coffee and Social Affairs Limited, announced this past April the securing of a new coffee shop location. This location is in The Arts Theatre in London's world famous West End.

DOCASA, via Department of Coffee and Social Affairs Limited, announced in May of this year that it secured a first liquor license for its newly extended and refurbished coffee shop in London's iconic Old Spitalfields Market. The Company’s coffee shops in Central London are in premium spots with foot traffic of greater than 1 million people daily.

Furthermore, this past August, DOCASA, via Department of Coffee and Social Affairs Limited, announced the launch in the United States of its award-winning specialty coffee shops, securing its initial site at 800 Diversy in Chicago, Illinois.

This new shop is the first of 6 initial planned shops in the Chicago area. Discussions were taking place on a further 5 throughout the city.

DOCASA, Inc. (DCSA), closed Tuesday's trading session at $1.24, up 12.73%, on 600 volume with 3 trades. The average volume for the last 60 days is 3,599 and the stock's 52-week low/high is $0.55/$3.00.

Esports Entertainment Group, Inc. (GMBL)

Real Pennies reported previously on Esports Entertainment Group, Inc. (GMBL), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Esports Entertainment Group, Inc. is a next generation, licensed, online gambling enterprise specifically focused on eSports wagering. The Company’s intention is to offer wagering on eSports events in a fully licensed, regulated, and secured platform to the international eSports audience, excluding the U.S. OTCQB-listed, Esports Entertainment Group has offices in St. Mary's, Antigua and Barbuda.

A team of industry and technical experts from the online gambling and video game industries, and e-Sports, marketing, legal, and financial professionals lead Esports Entertainment Group. Fundamentally, Esports Entertainment Group is a licensed online gambling enterprise with a particular emphasis on eSports wagering and 18+ gaming.

The Company also intends to offer users worldwide the ability to participate in multi-player video games tournaments online for cash prizes. Currently, Esports Entertainment Group is developing a number of play money websites and its real money wagering website.

Esports Entertainment Group has been issued a Client Provider Authorization Permit by the Kahnawake Gaming Commission. Esports has applied for an Interactive Wagering License with the Financial Services Regulatory Commission of Antigua and Barbuda to conduct real money interactive gaming on a global basis from centers in Canada and Antigua.

The Company also has an agreement with CAMS, LLC to provide international electronic payment and risk management solutions. Esports Entertainment Group has a peer-to-peer wagering system. It will provide real money betting exchange style wagering on all professional eSports events.

Esports is concentrating on launching its online Esports gambling platform. This platform will be completely licensed and the highest regulated esports gambling site globally.

Last month, Esports Entertainment Group announced the signing of an Affiliate Marketing Agreement with Better Collective in preparation for the soon coming launch of its Esports betting operations. The Company’s anticipation is that this Affiliate Marketing Agreement will generate 50,000 new customers for Esports Entertainment Group in its first full year. Better Collective is the world's foremost provider of betting tips, bookmaker information, and a builder of iGaming communities.

In early October, Esports Entertainment Group announced the execution of a Letter of Intent (LOI) to acquire all of the issued and outstanding securities of Ardmore Investments SP. Z O.O. Ardmore is a subsidiary of Switzerland based gambling software developer Swiss Interactive Software GmbH.

Since Esports’ year end at June 30, 2017, the Company signed more than 60 affiliates at Gamescom 2017. It also received its Curacao eGaming License, as well as announced an LOI to acquire its Bet Exchange Software Developer. Esports earlier entered into a Betting Gaming Platform Software Agreement with Swiss Interactive Software GmbH to provide wagering platform software.

Esports Entertainment Group, Inc. (GMBL), closed Tuesday's trading session at $2.29, down 2.55%, on 1,500 volume with 1 trade. The average volume for the last 60 days is 1,561 and the stock's 52-week low/high is $0.051/$3.14.

The Alkaline Water Company, Inc. (WTER)

Oakshire News Bulletin, StreetAuthority Financial, Penny Stock Rumble, InvestmentHouse, Investors Insights, Market FN, Wall Street Mover, SmallCapVoice, OTC Markets Group, MicroCap Gems, Investor Spec Sheet, and The Best Newsletters reported previously on The Alkaline Water Company, Inc. (WTER), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

The Alkaline Water Company, Inc. has developed an inventive, state-of-the-art, proprietary electrolysis beverage process, which produces healthy alkaline water. This water is packaged and sold in 500ml, 700ml, 1-liter, 3-liter and 1 gallon sizes under the trade name Alkaline88®. Alkaline88's premier alkaline water is a pH balanced bottled alkaline drinking water enhanced with trace minerals and electrolytes.

The Alkaline Water Company has its corporate office in Scottsdale, Arizona. The Company’s shares trade on the OTC Markets Group’s OTCQB. Alkaline88® ranks among the fastest-growing premium bottled water brands, with revenue increasing over 2,100 percent since Fiscal Year (FY) 2013.

The design of Alkaline88 is to encourage daily consumption of Alkaline Water via a consumer-oriented bulk delivery system targeted at removing expensive small bottles from the distribution supply chain. The production of Alkaline88 is at an 8.8 pH, intended to achieve optimal body balance.

Alkaline88 contains trace Himalayan minerals. The Company incorporated 84 beneficial trace Himalayan minerals to make Alkaline88 especially unique to other pH waters.

The Alkaline Water Company employs an advanced Electrochemically Activated Water (ECA) system to create 8.8 pH drinking water without the use of any chemicals. The ECA process utilizes specialized electronic cells coated with an assortment of rare earth minerals to produce scientifically engineered water.

The Alkaline Water Company has established key co-packing facilities across the United States to support its national expansion campaign. The Company currently has six co-packers across the nation that have up to a combined $72 million of production capabilities. These are situated within 600 miles of 95 percent of the U.S. population.

In less than five years, Alkaline88® has expanded to more than half of the top 75 food retailers and wholesalers in the United States. The Alkaline88® brand is presently available in greater than 32,000 retail locations across the nation. The expectation is that distribution will surpass 40,000 locations by the end of FY 2018.

In FY 2017, The Alkaline Water Company secured placement for Alkaline88® with VMC, Harris Teeter, Festival Foods, 7-Eleven stores (in Southern California), Fresh Thyme Farmers Market, Food Depot Supermarkets, Hornbacher's, Super One Foods, Food Lion, Winn-Dixie, BI-LO, Dierbergs Markets, Sendik's Food Market, and Ingles Markets.

This month, The Alkaline Water Company announced that Bodega Latina Corporation, dba El Super, is now selling Alkaline88® water in the 3-liter and 500ml sizes. The Company’s placement into El Super (number 64 on the Supermarket News list of 2017 Top 75 Retailers and Wholesalers) makes Alkaline88® available in more than 32,000 retail locales across the nation.

The Alkaline Water Company, Inc. (WTER), closed Tuesday's trading session at $1.21, up 10.00%, on 11,688 volume with 25 trades. The average volume for the last 60 days is 15,024 and the stock's 52-week low/high is $0.85/$2.04.

Algodon Wines & Luxury Development Group, Inc. (VINO)

OTC Markets Group, MarketWatch, Marketwired, Stock News Now, and Stockhouse reported on Algodon Wines & Luxury Development Group, Inc. (VINO), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Algodon Wines & Luxury Development Group, Inc. (Algodon Group) is a luxury lifestyle and real estate development brand with premium wines in Argentina. The Company identifies and develops vineyard operations, lifestyle properties, and other real estate assets and luxury brands in Argentina, and potentially more in other important areas of South America and internationally. Algodon Group is based in New York City. The Company also has offices in Buenos Aires and Mendoza.

Algodon’s current real estate developments include a Buenos Aires luxury boutique hotel, Algodon Mansion, in the city's most elegant residential neighborhood of Recoleta, and also the Mendoza wine resort, Algodon Wine Estates. This is a luxury vineyard estate in San Rafael, Argentina.

Algodon (using Algodon's icon wines as its ambassador) identifies and develops hotel, hospitality, and other lifestyle properties, and opportunities and brands that fit within its proprietary Algodon® brand.

Algodon Group announced in October of 2016 that it was awarded a gold medal in the Global Malbec Masters 2016 Wine Competition for its 2012 Black Label Malbec. The Global Malbec Masters (organized by The Drinks Business) is a prestigious series of blind tasting competitions, designed to reward the very best Malbecs around the world, ranging from the mountains of Mendoza and Chile's Maipo Valley to the châteaux of Cahors.

The 2012 Black Label Malbec represents the best selection from Algodon Fine Wines’ 1946 Malbec vines. The Black Label Malbec spends two years in new French oak after the microvinification method. The grapes undergo harvesting in late February, and are carefully selected directly in the vineyards.

Algodon Wine Estates is in San Rafael, Mendoza, in the foothills of the Sierra Pintadas. It produces a complete range of premium wines from land holdings that include noted parcels of pre-phylloxera vineyards dating back to the 1940s.

The Mendoza winery in the southernmost region of Argentina's wine capital is fed by the purest meltwater from the glacial Andes. Greater than 325 acres of vines go back as far as 1946 and produce first-rate fruit on sandy and clay loam.

Earlier in 2017, Algodon Wines & Luxury Development Group announced it partnered with The Eden Residence Club. This is to offer luxury services exclusively to Algodon Wine Estates homeowners and Algodon Group shareholders. The Eden Club is a global Private Members' Golf Club located in St Andrews, Scotland.

In May of this year, Algodon Wines & Luxury Development Group announced it partnered with Sherry-Lehmann Wine & Spirits to bring Algodon Fine Wines' portfolio of award-winning Malbec wines produced in the San Rafael, Mendoza wine region of Argentina to the U.S. This partnership represents Algodon Fine Wines' initial U.S. retailer. Sherry-Lehmann Wine & Spirits is a foremost wine and spirits merchant.

Algodon has completed the strategic acquisition of more land directly adjacent to the existing Algodon property. The new parcel measures 845 hectares or 2,088 acres. This more than doubles the size of Algodon Wine Estates.

Algodon Wines & Luxury Development Group, Inc. (VINO), closed Tuesday's trading session at $1.00, even for the day, on 3,810 volume with 6 trades. The average volume for the last 60 days is 1,213 and the stock's 52-week low/high is $0.80/$2.50.

Cantabio Pharmaceuticals, Inc. (CTBO)

Leeb’s Market Forecast, OTCtipReporter, PennyStockScholar, Profitable Trader Authority, AwesomeStocks, HotStockProfits, ProfitableTrading, and Investors Alley reported earlier on Cantabio Pharmaceuticals, Inc. (CTBO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Cantabio Pharmaceuticals, Inc. concentrates on bringing novel, first-in-class drug candidates into clinical trials and beyond. The OTCQB-listed Company does so through the discovery and development of inventive pharmacological chaperone and protein delivery based therapeutics, centering on protein systems implicated in neurodegenerative disorders. These include Alzheimer’s, Parkinson’s, and oxidative stress. Currently, Cantabio is engaging in advanced pre-clinical trials of its therapeutic candidates and is focused on developing these towards clinical trials.

Cantabio Pharmaceuticals, Inc. was established via the merger of Gardedam Therapeutics with Cantabio Pharmaceuticals in November of 2015. A preclinical stage biotechnology company, Cantabio Pharmaceuticals is based in Sunnyvale, California.

The Company is focusing on commercializing novel therapies and the Intellectual Property (IP) generated from its research and development (R&D) activities for Parkinson’s disease (PD), Alzheimer’s disease (AD), and other related neurodegenerative diseases. Its corporate strategy mixes a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach.

This particular approach is now identifying and developing small molecule pharmacological chaperones for clinical trials. Moreover, Cantabio is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins that display loss of function during disease conditions.

The Company has a new preclinical therapeutic program for Alzheimer’s disease that it is pursuing by way of its drug discovery partnership with NovAliX. This program is targeted at the development of small molecule chaperones, which stabilize the Abeta peptide, the aggregation of which is considered to be a critical element in the onset and progression of Alzheimer’s disease.

Cantabio Pharmaceuticals announced in July 2017 a publication lead authored by its Chief Executive Officer (CEO), Dr. Gergely Tóth, along with collaborators at the University of Cambridge, in the peer-reviewed journal ACS Chemical Neuroscience. The article is titled Detection and Characterization of Small Molecule Interactions with Fibrillar Protein Aggregates using Microscale Thermophoresis. It reported on a novel and general methodology for studying small molecule and protein fibril interactions. It demonstrated that one of the Company’s lead Tau targeting pharmacological chaperone molecules binds to Tau fibrils with high affinity.

Last month, Cantabio Pharmaceuticals announced a publication lead authored by CEO Dr. Gergely Tóth, along with collaborators at the Hungarian Academy of Sciences and Hungarian Brain Research Program, in the peer-reviewed journal Biochimica et Biophysica Acta - General Subjects.

The article, Structural features of human DJ-1 in distinct Cys106 oxidative states and their relevance to its loss of function in disease, investigated a structure and biophysics-based mechanism by which the DJ-1 protein may lose its neuroprotective function because of high oxidative stress conditions that are present in brain cells of patients with neurodegenerative diseases such as AD and PD.

Cantabio Pharmaceuticals, Inc. (CTBO), closed Tuesday's trading session at $0.04, up 2.56%, on 15,000 volume with 2 trades. The average volume for the last 60 days is 39,564 and the stock's 52-week low/high is $0.0231/$0.40.

TechCare Corp. (TECR)

PennyStockTweets, Investors Hangout, InvestorsHub, OTC Markets, Investing, Barchart, Stockhouse, 4-Traders, GuruFocus, and Emerging Growth reported on TechCare Corp. (TECR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A technology enterprise, TechCare Corp. has a pioneering delivery platform that utilizes vapor technology for natural health and beauty treatments. The Company engages in the design, development, and commercialization of this unique delivery platform employing vaporization of different natural, plant-based compounds, to enable a broad array of treatment solutions. TechCare is headquartered in New York, New York and the Company lists on the OTCQB.

TechCare has a strategic partnership agreement with HoMedics, one of the world's top brands in health and wellness products. HoMedics will manufacture, market, as well as distribute TechCare's Novokid products in the U.S., Canada, Brazil, Argentina, Colombia, and Costa Rica. The products will be co-branded as HoMedics products powered by TechCare.

Novokid consists of a portable device that vaporizes TechCare's all-natural, plant-based solution contained in a disposable capsule. It comes with a proprietary head cap. TechCare’s Novokid has received CE Mark approval as a CLASS I Medical Device.

Novokid is the first of its type home use device. It presents a scientifically proven solution to eliminate lice, super lice, and also eggs. Novokid is 100 percent natural, plant-based and pesticide-free. Novokid uses a proprietary vapor-based delivery platform.

Novokid utilizes a simple 10 minute dry treatment. This treatment necessitates no rinsing or washing. The treatment is quick, dry, and clean. In addition, it is easily administered at home or while mobile. Additionally, Novokid can be used as a maintenance and preventative treatment if used regularly.

In April 2017, TechCare announced that it filed a patent with the U.S. Patent and Trademark Office (USPTO) for its invention titled, "Treating an object with a gaseous compound in an airtight space". The Company was earlier issued patents in the United States and Europe for other components of its proprietary cold vapor technology platform. This includes one for treating head lice with gaseous compounds in an airtight space.

In late August of this year, TechCare and Natur Holdings B.V. announced the signing of a Memorandum of Understanding (MOU) to combine the operations of the two companies in an all-stock transaction to create a high-tech healthcare, wellness, healthy food, and beauty consumer products leader. Natur is Europe's first high-tech, Health Company transforming natural juices and snacks consumption.

Under the terms of the MOU, TechCare will acquire the assets, operations, and activities of Natur. This is in return for the issuance of TechCare common stock, representing 50 percent of the issued and outstanding common stock, on a fully diluted basis, immediately following their issuance.

TechCare Corp. (TECR), closed Tuesday's trading session at $0.36, even for the day. The average volume for the last 60 days is 2,078 and the stock's 52-week low/high is $0.10/$1.50.

Vycor Medical, Inc. (VYCO)

PennyStockScholar, FeedBlitz, OTCtipReporter, and Wall Street Resources reported earlier on Vycor Medical, Inc. (VYCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Vycor Medical, Inc. is a provider of distinct and first-class surgical and therapeutic solutions. The Company operates two business units - Vycor Medical and NovaVision. Both of these business units adopt a minimally or non-invasive approach. Vycor Medical has U.S. Food and Drug Administration (FDA) 510(k) clearance for brain and spine surgeries and regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea, Japan, Russia, and Taiwan. Vycor Medical is based in Boca Raton, Florida.

The Company’s NovaVision provides non-invasive, computer-based rehabilitation targeted at a substantial and largely un-addressed market of people who have lost their sight because of stroke or brain injury. The NovaVision business unit develops and provides science-driven neurostimulation therapy and other medical technologies. This helps improve and partially restore sight in patients with neurological vision impairments.

Vycor Medical’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices. These have the potential for quicker, safer, and also more economical brain surgeries, as well as faster patient discharge.

The design of VBAS is to optimize neurosurgical site access and reduce patient risk. In addition, the design of VBAS is to expedite recovery and add tangible value to the professional medical community.

The Company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (TBI), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the United States targeted at the restoration of vision for neurologically induced vision loss.

Vycor Medical has developed NeuroEyeCoach™. This is a therapy that is highly complementary to VRT™. NeuroEyeCoach™ is a compensation therapy registered in the United States as a Class I 510(k) exempt device. The design of NeuroEyeCoach is to improve a patient's ability to scan their environment more efficiently. NeuroEyeCoach is NovaVision's eye movement compensation therapy for patients who have suffered a cerebral visual field disorder due to a stroke or brain injury.

In August, Vycor Medical reported financial results for the three and six months ended June 30, 2017. The Company’s Revenues for the six months ended June 30, 2017 were $736,000 versus $779,000 for the same period the year prior. Cash Operating Loss was $235,000, versus $329,000 for the same period in 2016. This represents a reduction of 29 percent. Operating Loss was $654,000, versus $806,000. This represents a reduction of 19 percent.

During the period, the US patent office (USPTO) issued/allowed four patents. These are all directed to the integration of neuro-navigation systems with Vycor Medical's VBAS retractor system.

The patents complement and strengthen the Company’s existing patent portfolio. This is especially in relation to Vycor’s continuing emphasis to more fully integrate its VBAS product range with neuro-navigation systems without sacrificing the surgeon's ability to visually inspect the surrounding tissue as the devices undergo insertion.

Vycor Medical, Inc. (VYCO), closed Tuesday's trading session at $0.34, even for the day. The average volume for the last 60 days is 5,212 and the stock's 52-week low/high is $0.45/$0.122.

graphic

The QualityStocks
Company Corner

graphic
graphic

Cache Elite Inc. (ILUS)

The QualityStocks Daily Newsletter would like to spotlight Cache Elite Inc. (ILUS). Today, Cache Elite Inc. closed trading at $0.0097, up 31.08%, on 1,480,129 volume with 59 trades. The stock’s average daily volume over the past 60 days is 210,072 and its 52-week low/high is $0.0021/$0.065.

Cache Elite Inc. (ILUS), a forward-thinking technology and service provider offering homeowners with the latest in 3D designs, decorative hardware, and travel and vacation services, announces that it has engaged the corporate communications expertise of NetworkNewsWire ("NNW"). "2017 has been a year of considerable growth as we focused on building a foundation that would act as a catalyst for increased market strength, transparency, and corporate and shareholder value," says Cache Elite CEO Derrick McWilliams. "We have worked hard to achieve these goals and increase shareholder value for the long-run, and look forward to working with NNW to continue to communicate our strategies and achievements to the investment community."

Cache Elite Inc. (ILUS) is a forward-thinking technology and service provider. The company provides homeowners with the latest in 3D designs, decorative hardware (http://www.eliteknobs.com), and travel and vacation services. Its foray into travel-related services can be found at the TripWitz website (http://www.tripwitz.com) where its proprietary back-end software, called Internet Travel Management Software, helps TripWitz provide its customers with a distinctive, cost-effective and perfect travel experience that sets it apart from other online travel agencies such as Expedia and Travelocity.

TripWitz provides real-time, dynamically packaged vacation quotes that include airfare, hotels, villas, ground transportation and activities. Every client searching for a smarter way to travel will find TripWitz is able to cut out the stress and frustrations found with other online travel agents. The company provides its intuitive travel services to clients searching vacations possibilities at more than 20,000 destinations around the globe.

TripWitz contracts with over 500,000 hotels and connects with the world's airlines through Google's ITA Gateway software that allows for advanced availability solutions to satisfy millions of queries per second at the lowest possible fares. Seasonal rate fluctuations for many travel services, including ground transportation options, are included in the company's software, giving clients the best possible rates. TripWitz prides itself on giving users a friendly vacation experience that includes access to an experienced vacation destination specialist. Customers are never left to fend for themselves at any point of their vacation experience. TripWitz is also accepting Bitcoins, the international cryptocurrency, as payment for not only flights but vacations as well.

A new report published by Allied Market Research projects the global online travel market will reach an estimated $1,091 billion by 2022, with the Asia-Pacific region expected to witness the highest growth during the forecast period. Travelers are looking for sound help in making travel decisions that fit within their budgets. Younger travelers, those within the 21-31 year age bracket, are seen as a more mobile generation, using social media and smartphones for many of their travel planning and booking needs.

TripWitz is an accredited member of the CCRA (Travel Commerce Network), which connects the company to over 180,000 properties worldwide. TripWitz is also an ARC approval agency. ARC accredited agencies are the most select group of dedicated professionals in the U.S. travel industry and are recognized as having met stringent financial, personnel and security requirements.

The official press release announcing the recent launch of TripWitz can be found at the following link: Cache Elite Inc. (ILUS) Unveils New Venture Into the $341 Billion Travel Industry. Disclaimer

Cache Elite Inc. Blog

Cache Elite Inc. News:

Cache Elite Inc. (ILUS) Engages NetworkNewsWire for Corporate Communications Solutions

Cache Elite Inc. (ILUS) is “One to Watch”

A New Audio Interview with Cache Elite, Inc. CEO, Derrick McWilliams, is now at SmallCapVoice.com

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.3566, up 11.44%, on 705,822 volume with 286 trades. The stock’s average daily volume over the past 60 days is 514,723, and its 52-week low/high is $0.09/$0.72.

NetworkNewsWire Editorial Coverage: According to a recent Haywood Securities research report, the value of the cannabidiol (CBD) market is expected to hit $2.1 billion by 2020. CBD is just one compound out of more than 90 found within the cannabis plant, though. While many companies with an interest in medicinal marijuana pursue various avenues to extract cannabinoids, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) has developed a proprietary process capable of extracting all 90+ cannabinoids in a laboratory setting, eliminating most of the costly requirements that typically come with cannabinoid extraction.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

Economic Impact of Biosynthesis on the Cannabis Industry

NetworkNewsWire Announces Publication Highlighting Innovations in Cannabis R&D

NetworkNewsWire Announces Publication Discussing Advanced Technology in Cannabinoid R&D

EVIO, Inc. (EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $0.55, off by 1.79%, on 32,342 volume with 38 trades. The stock’s average daily volume over the past 60 days is 14,603, and its 52-week low/high is $0.49/$5.45.

EVIO, Inc. (EVIO) the nation's leading provider of analytical laboratory cannabis testing services, is pleased to announce that it has expanded testing capabilities in its Yuba City laboratory. In anticipation of California's new testing rules which are scheduled to commence on January 1, 2018, EVIO has invested in additional instrumentation to offer a full suite of testing services including pesticide, microbiological, and expanded cannabinoid potency testing.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

EVIO, Inc. Expands Testing Services at its Northern California Laboratory

EVIO Labs Expands to Fifth Oregon Location

EVIO Labs Sees Demand for Testing Services Double

Patriot One Technologies, Inc. (TSX.V:PAT) (OTCQB:PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $1.1437, off by 7.53%, on 271,431 volume with 202 trades. The stock’s average daily volume over the past 60 days is 175,059, and its 52-week low/high is $0.4665/$1.54.

Patriot One Technologies, Inc. (TSX.V:PAT) (OTCQB:PTOTF) was pleased to announce the closing of its recently announced bought deal equity financing. The Company sold 9,602,500 units (the "Units") at a price of $1.20 per Unit for gross proceeds of $11,523,000 (the "Offering"), which included 1,252,500 Units sold pursuant to the full exercise of the Underwriters' over-allotment option. Each Unit consists of one common share of the Company (a "Common Share") and one half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant").

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

Patriot One Technologies Inc. Announces Closing of $11.5 Million Bought Deal Offering

Patriot One Technologies Inc. Announces an Increase to the Previously Announced Bought Deal Financing

Patriot One Technologies Inc. Announces $8.5 Million Bought Deal

Greenkraft, Inc. (GKIT)

The QualityStocks Daily Newsletter would like to spotlight Greenkraft, Inc. (GKIT). Today, Greenkraft, Inc. closed trading at $0.107, off by 1.38%, on 6,100 volume with 4 trades. The stock’s average daily volume over the past 60 days is 11,141 and its 52-week low/high is $0.02/$0.20.

Greenkraft, Inc. (GKIT), a nationally recognized player in the alternative fuel engine and truck market, today announces that it has signed supply contracts with several dealers and distributors looking to provide to their customers a range of efficient eco-friendly commercial trucks. Greenkraft's Model G line of fuel efficient, versatile commercial trucks will offer businesses in the delivery and service sectors a wide choice of reliable, cost-effective vehicles. The Company's globally manufactured commercial truck line consists of 18 different models ranging from Classes 4 to 7, all of which meet EPA and CARB emission standards.

Greenkraft, Inc. (GKIT) is a nationally recognized company specializing in the production of alternative fuel automotive products, including engines and commercial trucks. Located in Santa Ana, California, the company's mission is to provide clean, green, energy efficient automotive products that have a price advantage coupled with unparalleled American performance. Established in 2008, Greenkraft, Inc. serves the commercial truck market powered by the alternative fuels CNG and LPG in classes 4, 5, 6 and 7.

Greenkraft's new line of trucks, known as the G3 and G4, will accommodate weights of 26,000 lbs. and 33,000 lbs., respectively. George Gemayel, CEO of Greenkraft, Inc., said the demand for larger trucks that run on alternative fuels continues to increase.

"Greenkraft is going to revolutionize the trucking industry with these new 26,000 and 33,000 lbs. trucks that run on CNG and PROPANE fuel," Gemayel states in a press release. "The only way we can meet increased demand for Greenkraft products is to expand our current factory. This expansion is one of many factors that will substantially increase the Company's revenue in 2017."

Greenkraft produces a cab forward design for its commercial trucks, which allows the passenger area to be much larger than in other similar sized vehicles. Several tank capacity options exist, making it easy to select the most efficient model for a client's specific needs. Greenkraft is one of the only companies in the world to offer a refrigeration option with an alternative fuel truck – an essential, must-have option for many businesses.

Greenkraft trucks, considered among the best performing in the heavy-duty market, are used in a variety of industries and in some of the nation's largest cities. The company also offers a line of trucks designed to run with a package from Allison Transmission Holdings, Inc. (NYSE: ALSN), which gives clients the option of purchasing a fully automatic transmission vehicle. This option expands the size of the driver pool since fully automatic shifting reduces driver fatigue, contributes to solving the issue of driver retention, and it is easy to use.

CNG and LPG conversion systems made by Greenkraft are available for several major automobile brands including Ford, GM and Isuzu/GM. Installation, service, parts and warranty are all available through Greenkraft facilities and its partners. Disclaimer

Greenkraft, Inc. Blog

Greenkraft, Inc. News:

Greenkraft, Inc. (OTCQB: GKIT) Signs Supply Contracts for its Alternative Fuel Commercial Trucks, Rising to Meet Industry Demand

Greenkraft, Inc.'s (GKIT) Alternative Fuel Engine Awarded Certification for Exceeding California's Clean Air Act Standards

Greenkraft, Inc. Expands Distribution Network to Meet Increased Product Demand

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.018, off by 1.64%, on 1,068,016 volume with 48 trades. The stock’s average daily volume over the past 60 days is 3,266,697, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (GOHE) is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. successfully hosted a joint networking event last week in Las Vegas, NV with fellow companies in the cannabis financial market sector; Fusion Bank, Integrated Compliance Solutions, LLC, and NICCE Exchange. The event brought together key individuals and entities from different areas across the west coast who are involved with the fast-growing cannabis industry. This event provided them with a solid platform to engage, network, and obtain a wealth of knowledge and information about the service offerings of the companies hosting the event, each of whom is making strides in their efforts to deliver the most effective financial technology and banking solutions to the cannabis industry.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout’s MoneyTrac Technology, Inc. Co-Hosts Finance and Technology Networking Event for the Cannabis Industry

Global Payout's MoneyTrac Technology, Inc. Ramps-Up Sales and Marketing Efforts in Los Angeles County for PotSaver Brand

Global Payout’s MoneyTrac Technology, Inc. Partners with Innovative Blockchain and Token Accelerator Pegasus Fintech, Inc. for Joint Development of Cryptocurrency-Based Token

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.3901, off by 1.74%, on 104,394 volume with 46 trades. The stock’s average daily volume over the past 60 days is 103,636 and its 52-week low/high is $0.1701/$0.699.

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP) a drug delivery platform innovator, announces it has received a new Notice of Allowance from the United States Patent and Trademark Office for the use of its technology as a delivery platform for all cannabinoids including THC; fat soluble vitamins; non steroidal anti-inflammatory pain medications (NSAIDs); and nicotine.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Bioscience Receives Groundbreaking U.S. Patent Allowance for its DehydraTECH™ Delivery of THC, NSAIDs, Nicotine and Vitamins

NetworkNewsWire Announces Publication Highlighting Recent Developments in Drug Delivery Technologies

NetworkNewsWire Announces Publication Highlighting Key Players in Big Pharma M&A

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

OTCBB Journal
(PYDS) +80.16%

2.

Wall Street Mover
(BFNH) +40.46%

3.

Penny Stock Titans
(EVLI) +35.53%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251